Small and mid cap stocks in the chemical and pharmaceutical sectors have been among key gainers over the last month. HDFC Securities in a recent report highlighted that a majority of the better known names within this space have gained over 20 per cent since mid-April.
The upward move, according to them, is due to the China+1 strategy adopted by international buyers, higher commodity costs due to supply disruption and Covid related demand upsurge. While some of the stock gains could sustain going ahead and are news driven, other stocks have run ahead of fundamentals and may correct or consolidate